Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene.
Identifieur interne : 002256 ( PubMed/Checkpoint ); précédent : 002255; suivant : 002257Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene.
Auteurs : Chunling Ma [République populaire de Chine] ; Kun Yao ; Feng Zhou ; Minsheng ZhuSource :
- Cellular & molecular immunology [ 1672-7681 ] ; 2006.
Descripteurs français
- KwdFr :
- Adenoviridae, Animaux, Cellules Vero, Femelle, Plasmides, Protéines nucléocapside (génétique), Protéines nucléocapside (immunologie), Souris, Souris de lignée BALB C, Vaccins antiviraux (immunologie), Vaccins à ADN (immunologie), Vecteurs génétiques, Virus du SRAS (génétique), Virus du SRAS (immunologie).
- MESH :
- génétique : Protéines nucléocapside, Virus du SRAS.
- immunologie : Protéines nucléocapside, Vaccins antiviraux, Vaccins à ADN, Virus du SRAS.
- Adenoviridae, Animaux, Cellules Vero, Femelle, Plasmides, Souris, Souris de lignée BALB C, Vecteurs génétiques.
English descriptors
- KwdEn :
- MESH :
- chemical , genetics : Nucleocapsid Proteins.
- chemical , immunology : Nucleocapsid Proteins, Vaccines, DNA, Viral Vaccines.
- genetics : SARS Virus.
- immunology : SARS Virus.
- Adenoviridae, Animals, Chlorocebus aethiops, Female, Genetic Vectors, Mice, Mice, Inbred BALB C, Plasmids, Vero Cells.
Abstract
In order to investigate immunogenicity in the induction of humoral and cellular immune responses, severe acute respiratory syndrome associated coronavirus (SARS-CoV)-N gene recombinant replication-defective adenoviral vector, rAd-N, was generated and immunized BALB/c mice in a pcDNA3.1-N prime-rAd-N boost regimen. After humoral and cellular immune response detection, different levels of SARS-CoV N protein specific antibodies and interferon-gamma (IFN-gamma) secretion are shown compared to controls. The humoral immune response was induced more effectively by the DNA priming and recombinant adenovirus boosting regimen. There is a significant difference between heterogeneous and homologous vaccinations. The heterogeneous combinations were all higher than those of the homologous combinations in the induction of anti-N antibody response. Among the three heterogeneous combinations, pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N/rAd-N induced the strongest antibody response. In the induction of IFN-gamma production, the homologous combination of rAd-N/rAd-N/rAd-N/rAd-N was significantly stronger than that of pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N, but was relatively weaker than the heterogeneous combination of pcDAN3.1-N/pcDAN3.1-N/pcDAN3.1-N/rAd-N. This combination was a most efficient immunization regimen in induction of SARS-CoV-N-specific (IFN-gamma) secretion just as the antibody response. These results suggest that DNA immunization followed by recombinant adenovirus boosting could be used as a potential SARS-CoV vaccine.
PubMed: 17257500
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:17257500Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene.</title><author><name sortKey="Ma, Chunling" sort="Ma, Chunling" uniqKey="Ma C" first="Chunling" last="Ma">Chunling Ma</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, Nanjing Medical University, Nanjing 210029, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Microbiology and Immunology, Nanjing Medical University, Nanjing 210029</wicri:regionArea><wicri:noRegion>Nanjing 210029</wicri:noRegion></affiliation></author><author><name sortKey="Yao, Kun" sort="Yao, Kun" uniqKey="Yao K" first="Kun" last="Yao">Kun Yao</name></author><author><name sortKey="Zhou, Feng" sort="Zhou, Feng" uniqKey="Zhou F" first="Feng" last="Zhou">Feng Zhou</name></author><author><name sortKey="Zhu, Minsheng" sort="Zhu, Minsheng" uniqKey="Zhu M" first="Minsheng" last="Zhu">Minsheng Zhu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:17257500</idno><idno type="pmid">17257500</idno><idno type="wicri:Area/PubMed/Corpus">001F13</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F13</idno><idno type="wicri:Area/PubMed/Curation">001F13</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001F13</idno><idno type="wicri:Area/PubMed/Checkpoint">002256</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002256</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene.</title><author><name sortKey="Ma, Chunling" sort="Ma, Chunling" uniqKey="Ma C" first="Chunling" last="Ma">Chunling Ma</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology and Immunology, Nanjing Medical University, Nanjing 210029, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Microbiology and Immunology, Nanjing Medical University, Nanjing 210029</wicri:regionArea><wicri:noRegion>Nanjing 210029</wicri:noRegion></affiliation></author><author><name sortKey="Yao, Kun" sort="Yao, Kun" uniqKey="Yao K" first="Kun" last="Yao">Kun Yao</name></author><author><name sortKey="Zhou, Feng" sort="Zhou, Feng" uniqKey="Zhou F" first="Feng" last="Zhou">Feng Zhou</name></author><author><name sortKey="Zhu, Minsheng" sort="Zhu, Minsheng" uniqKey="Zhu M" first="Minsheng" last="Zhu">Minsheng Zhu</name></author></analytic><series><title level="j">Cellular & molecular immunology</title><idno type="ISSN">1672-7681</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenoviridae</term><term>Animals</term><term>Chlorocebus aethiops</term><term>Female</term><term>Genetic Vectors</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Nucleocapsid Proteins (genetics)</term><term>Nucleocapsid Proteins (immunology)</term><term>Plasmids</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>Vaccines, DNA (immunology)</term><term>Vero Cells</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adenoviridae</term><term>Animaux</term><term>Cellules Vero</term><term>Femelle</term><term>Plasmides</term><term>Protéines nucléocapside (génétique)</term><term>Protéines nucléocapside (immunologie)</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins à ADN (immunologie)</term><term>Vecteurs génétiques</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Nucleocapsid Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Nucleocapsid Proteins</term><term>Vaccines, DNA</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Protéines nucléocapside</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Protéines nucléocapside</term><term>Vaccins antiviraux</term><term>Vaccins à ADN</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adenoviridae</term><term>Animals</term><term>Chlorocebus aethiops</term><term>Female</term><term>Genetic Vectors</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Plasmids</term><term>Vero Cells</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adenoviridae</term><term>Animaux</term><term>Cellules Vero</term><term>Femelle</term><term>Plasmides</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Vecteurs génétiques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In order to investigate immunogenicity in the induction of humoral and cellular immune responses, severe acute respiratory syndrome associated coronavirus (SARS-CoV)-N gene recombinant replication-defective adenoviral vector, rAd-N, was generated and immunized BALB/c mice in a pcDNA3.1-N prime-rAd-N boost regimen. After humoral and cellular immune response detection, different levels of SARS-CoV N protein specific antibodies and interferon-gamma (IFN-gamma) secretion are shown compared to controls. The humoral immune response was induced more effectively by the DNA priming and recombinant adenovirus boosting regimen. There is a significant difference between heterogeneous and homologous vaccinations. The heterogeneous combinations were all higher than those of the homologous combinations in the induction of anti-N antibody response. Among the three heterogeneous combinations, pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N/rAd-N induced the strongest antibody response. In the induction of IFN-gamma production, the homologous combination of rAd-N/rAd-N/rAd-N/rAd-N was significantly stronger than that of pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N, but was relatively weaker than the heterogeneous combination of pcDAN3.1-N/pcDAN3.1-N/pcDAN3.1-N/rAd-N. This combination was a most efficient immunization regimen in induction of SARS-CoV-N-specific (IFN-gamma) secretion just as the antibody response. These results suggest that DNA immunization followed by recombinant adenovirus boosting could be used as a potential SARS-CoV vaccine.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17257500</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1672-7681</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>6</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Cellular & molecular immunology</Title><ISOAbbreviation>Cell. Mol. Immunol.</ISOAbbreviation></Journal><ArticleTitle>Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene.</ArticleTitle><Pagination><MedlinePgn>459-65</MedlinePgn></Pagination><Abstract><AbstractText>In order to investigate immunogenicity in the induction of humoral and cellular immune responses, severe acute respiratory syndrome associated coronavirus (SARS-CoV)-N gene recombinant replication-defective adenoviral vector, rAd-N, was generated and immunized BALB/c mice in a pcDNA3.1-N prime-rAd-N boost regimen. After humoral and cellular immune response detection, different levels of SARS-CoV N protein specific antibodies and interferon-gamma (IFN-gamma) secretion are shown compared to controls. The humoral immune response was induced more effectively by the DNA priming and recombinant adenovirus boosting regimen. There is a significant difference between heterogeneous and homologous vaccinations. The heterogeneous combinations were all higher than those of the homologous combinations in the induction of anti-N antibody response. Among the three heterogeneous combinations, pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N/rAd-N induced the strongest antibody response. In the induction of IFN-gamma production, the homologous combination of rAd-N/rAd-N/rAd-N/rAd-N was significantly stronger than that of pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N/pcDNA3.1-N, but was relatively weaker than the heterogeneous combination of pcDAN3.1-N/pcDAN3.1-N/pcDAN3.1-N/rAd-N. This combination was a most efficient immunization regimen in induction of SARS-CoV-N-specific (IFN-gamma) secretion just as the antibody response. These results suggest that DNA immunization followed by recombinant adenovirus boosting could be used as a potential SARS-CoV vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Chunling</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Nanjing Medical University, Nanjing 210029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Kun</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Feng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Minsheng</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Cell Mol Immunol</MedlineTA><NlmUniqueID>101242872</NlmUniqueID><ISSNLinking>1672-7681</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000256" MajorTopicYN="Y">Adenoviridae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="Y">Genetic Vectors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="Y">Plasmids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17257500</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><noCountry><name sortKey="Yao, Kun" sort="Yao, Kun" uniqKey="Yao K" first="Kun" last="Yao">Kun Yao</name><name sortKey="Zhou, Feng" sort="Zhou, Feng" uniqKey="Zhou F" first="Feng" last="Zhou">Feng Zhou</name><name sortKey="Zhu, Minsheng" sort="Zhu, Minsheng" uniqKey="Zhu M" first="Minsheng" last="Zhu">Minsheng Zhu</name></noCountry><country name="République populaire de Chine"><noRegion><name sortKey="Ma, Chunling" sort="Ma, Chunling" uniqKey="Ma C" first="Chunling" last="Ma">Chunling Ma</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002256 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002256 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:17257500
|texte= Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:17257500" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |